CO2020015305A2 - Agonistas del receptor de glp-1 y usos de los mismos - Google Patents
Agonistas del receptor de glp-1 y usos de los mismosInfo
- Publication number
- CO2020015305A2 CO2020015305A2 CONC2020/0015305A CO2020015305A CO2020015305A2 CO 2020015305 A2 CO2020015305 A2 CO 2020015305A2 CO 2020015305 A CO2020015305 A CO 2020015305A CO 2020015305 A2 CO2020015305 A2 CO 2020015305A2
- Authority
- CO
- Colombia
- Prior art keywords
- glp
- receptor agonists
- aza
- benzimidazoles
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
- C07C53/06—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
Abstract
Se proporcionan en la presente ácidos 6-carboxílicos de bencimidazoles y 4-aza , 5-aza y 7 aza bencimidazoles como agonistas de GLP-1R, procesos para elaborar tales compuestos y métodos que comprenden administrar tales compuestos a un mamífero en necesidad de los mismos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684696P | 2018-06-13 | 2018-06-13 | |
| US201962846944P | 2019-05-13 | 2019-05-13 | |
| US201962851206P | 2019-05-22 | 2019-05-22 | |
| PCT/IB2019/054867 WO2019239319A1 (en) | 2018-06-13 | 2019-06-11 | Glp-1 receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020015305A2 true CO2020015305A2 (es) | 2021-03-08 |
Family
ID=67003576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0015305A CO2020015305A2 (es) | 2018-06-13 | 2020-12-07 | Agonistas del receptor de glp-1 y usos de los mismos |
Country Status (39)
| Country | Link |
|---|---|
| US (5) | US10934279B2 (es) |
| EP (2) | EP3806955B9 (es) |
| JP (1) | JP6916968B1 (es) |
| KR (1) | KR102542199B1 (es) |
| CN (4) | CN112533674B (es) |
| AU (1) | AU2019285491B2 (es) |
| BR (1) | BR112020024470A2 (es) |
| CA (1) | CA3045644C (es) |
| CL (1) | CL2020003222A1 (es) |
| CO (1) | CO2020015305A2 (es) |
| CR (1) | CR20200612A (es) |
| CU (1) | CU20200099A7 (es) |
| CY (1) | CY1126097T1 (es) |
| DK (2) | DK3806955T3 (es) |
| EC (1) | ECSP20078651A (es) |
| ES (2) | ES3012643T3 (es) |
| FI (2) | FI3806955T3 (es) |
| GE (1) | GEP20237453B (es) |
| HR (2) | HRP20230631T1 (es) |
| HU (2) | HUE063074T2 (es) |
| IL (1) | IL279300B2 (es) |
| LT (2) | LT3806955T (es) |
| MA (1) | MA64510B1 (es) |
| MD (2) | MD3806955T3 (es) |
| MX (1) | MX389121B (es) |
| NI (1) | NI202000091A (es) |
| NZ (1) | NZ770240A (es) |
| PE (2) | PE20240584A1 (es) |
| PH (1) | PH12020552069A1 (es) |
| PL (2) | PL3806955T3 (es) |
| PT (2) | PT4219487T (es) |
| RS (2) | RS64323B9 (es) |
| SG (1) | SG11202011465QA (es) |
| SI (1) | SI3806955T1 (es) |
| TW (1) | TWI707683B (es) |
| UA (1) | UA124371C2 (es) |
| UY (1) | UY38261A (es) |
| WO (1) | WO2019239319A1 (es) |
| ZA (1) | ZA202007572B (es) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| US11858916B2 (en) | 2018-06-15 | 2024-01-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| CA3120499A1 (en) * | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CN113874019A (zh) * | 2019-05-20 | 2021-12-31 | 辉瑞大药厂 | 用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合 |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| US11702404B2 (en) | 2019-10-25 | 2023-07-18 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| TWI809334B (zh) * | 2019-12-10 | 2023-07-21 | 美商輝瑞股份有限公司 | ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式 |
| US12121511B2 (en) * | 2020-01-29 | 2024-10-22 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4458834A3 (en) | 2020-02-07 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN113493447B (zh) * | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CN115667250A (zh) * | 2020-04-29 | 2023-01-31 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| EP4166142A4 (en) * | 2020-06-10 | 2024-06-26 | Medshine Discovery Inc. | METHYL-SUBSTITUTED BENZOBISOXAZOLE COMPOUND AND USE THEREOF |
| WO2021254470A1 (zh) * | 2020-06-19 | 2021-12-23 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| IL300155A (en) | 2020-08-06 | 2023-03-01 | Gasherbrum Bio Inc | Heterocyclic GLP-1 agonists |
| TW202214622A (zh) * | 2020-08-06 | 2022-04-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｇｌｐ－１ｒ促效劑及其用途 |
| EP4204415A4 (en) * | 2020-08-28 | 2025-03-26 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| WO2022068772A1 (zh) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| EP4229050A4 (en) * | 2020-10-13 | 2024-12-11 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN114478694A (zh) * | 2020-11-13 | 2022-05-13 | 成都奥达生物科技有限公司 | 一种长效mc4r激动剂 |
| US11851419B2 (en) * | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| CN115461334B (zh) | 2020-11-27 | 2024-06-21 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN114591308B (zh) * | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
| US20220193063A1 (en) * | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Metabolites of glp1r agonists |
| US12065434B2 (en) | 2020-12-15 | 2024-08-20 | Pfizer Inc. | Metabolites of GLP1R agonists |
| WO2022165076A1 (en) * | 2021-01-28 | 2022-08-04 | Carmot Therapeutics, Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US20240217966A1 (en) | 2021-03-24 | 2024-07-04 | Shionogi & Co., Ltd. | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| WO2022225941A1 (en) | 2021-04-21 | 2022-10-27 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| JP2024516291A (ja) * | 2021-05-03 | 2024-04-12 | カーモット セラピューティクス インコーポレイテッド | ベンゾイミダゾイルｇｌｐ－１受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| EP4373821A1 (en) * | 2021-07-21 | 2024-05-29 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| MX2024001331A (es) * | 2021-08-04 | 2024-04-19 | Shanghai Hansoh Biomedical Co Ltd | Regulador derivado del cicloalqueno, método de preparación de este y su aplicación. |
| CN116419923B (zh) * | 2021-08-24 | 2024-09-06 | 东宝紫星(杭州)生物医药有限公司 | 咪唑并环类化合物及其应用 |
| CN118948849A (zh) | 2021-09-08 | 2024-11-15 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
| KR20240068737A (ko) * | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| CA3233131A1 (en) * | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057414A1 (en) * | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| CN115991685B (zh) * | 2021-10-20 | 2025-03-04 | 韶远科技（上海)有限公司 | 一种氧杂环丁烷-2-甲胺的制备方法 |
| TWI843243B (zh) * | 2021-10-22 | 2024-05-21 | 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 | 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途 |
| CA3236708A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| JPWO2023106310A1 (es) * | 2021-12-07 | 2023-06-15 | ||
| CN113974618B (zh) * | 2021-12-12 | 2022-09-13 | 广西澍源智能科技有限公司 | 基于水峰血糖修正的无创血糖测试方法 |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN118434730A (zh) * | 2021-12-23 | 2024-08-02 | 江苏恒瑞医药股份有限公司 | 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法 |
| CN118401518A (zh) * | 2021-12-23 | 2024-07-26 | 江苏恒瑞医药股份有限公司 | 一种glp-1受体激动剂的结晶形式及其制备方法 |
| CN116354945B (zh) * | 2021-12-27 | 2024-08-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| CN119343343A (zh) * | 2022-02-09 | 2025-01-21 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2023151575A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 |
| JP2025508914A (ja) * | 2022-02-28 | 2025-04-10 | アスカレシス バイオサイエンス カンパニー リミテッド | Ｇｌｐ－１ｒ調節化合物 |
| CN118974037A (zh) * | 2022-03-08 | 2024-11-15 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| WO2023228023A1 (en) * | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| KR20250047817A (ko) * | 2022-09-06 | 2025-04-04 | 민드랭크 테라퓨틱스 (수저우) 뉴 드러그 리서치 앤 디벨롭먼트 컴퍼니, 리미티드 | Glp-1r 작용제 화합물의 결정다형체 및 이의 제조 방법과 용도 |
| JP2025084137A (ja) * | 2022-09-22 | 2025-06-03 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CN120344520A (zh) | 2022-11-16 | 2025-07-18 | 伊莱利利公司 | 胰高血糖素样肽1受体激动剂 |
| CN115785066B (zh) | 2022-12-08 | 2024-05-31 | 广东工业大学 | 曲格列汀晶型f及其制备方法 |
| WO2024160271A1 (zh) * | 2023-02-02 | 2024-08-08 | 江苏豪森药业集团有限公司 | 一种环烯类化合物的盐、晶型及其制备方法和应用 |
| WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024214038A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| CN118812522A (zh) * | 2023-04-21 | 2024-10-22 | 苏州闻泰医药科技有限公司 | 一种glp-1r受体激动剂化合物盐、其晶型、其制备方法和应用 |
| WO2025015268A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Modulators of calcitonin receptor and/or amylin receptor activity |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| USD1011080S1 (en) | 2023-07-28 | 2024-01-16 | Voilasophy, Llc. | Yoga storage rack |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025104668A1 (en) | 2023-11-17 | 2025-05-22 | Pfizer Inc. | Anti-gastric inhibitory polypeptide receptor (gipr) antibodies and antibody conjugates for the treatment of metabolic disorders |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025140532A1 (en) * | 2023-12-27 | 2025-07-03 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
| WO2025140533A1 (en) * | 2023-12-27 | 2025-07-03 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE69413523T2 (de) | 1993-03-18 | 1999-05-12 | Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire | Benzimidazole derivate |
| AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
| EP1235572A2 (en) | 1999-10-29 | 2002-09-04 | MERCK SHARP & DOHME LTD. | Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| EP1351936A1 (en) | 2001-01-15 | 2003-10-15 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| JP2005532991A (ja) * | 2002-01-10 | 2005-11-04 | ニューロジェン・コーポレーション | メラニン凝集ホルモン受容体リガンド：置換２−（４−ベンジル−ピペラジン−１−イルメチル）−及び２−（４−ベンジル−ジアゼパン−１−イルメチル）−１ｈ−ベンゾイミダゾールアナログ |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| MY140489A (en) | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| BRPI1013579A2 (pt) | 2009-03-30 | 2020-11-03 | Transtech Pharma, Inc. | derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| WO2011097491A1 (en) * | 2010-02-04 | 2011-08-11 | Glaxosmithkline Llc | Benzimidazole antiviral agents |
| MX2012013130A (es) | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| PL2621493T3 (pl) | 2010-09-30 | 2017-01-31 | Pfizer Inc. | N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| US20150376198A1 (en) | 2013-02-18 | 2015-12-31 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| WO2016029146A1 (en) | 2014-08-22 | 2016-02-25 | University Of Washington | Specific inhibitors of methionyl-trna synthetase |
| US20180305334A1 (en) | 2015-10-14 | 2018-10-25 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| PT3397631T (pt) | 2015-12-29 | 2021-05-28 | Pfizer | 3-azabiciclo[3.1.0]hexanos substituídos como inibidores de cetoexocinase |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| RU2740135C1 (ru) * | 2016-12-16 | 2021-01-11 | Пфайзер Инк. | Агонисты рецептора glp-1 и их применение |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CN113874019A (zh) * | 2019-05-20 | 2021-12-31 | 辉瑞大药厂 | 用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合 |
-
2019
- 2019-06-10 CA CA3045644A patent/CA3045644C/en active Active
- 2019-06-10 US US16/436,311 patent/US10934279B2/en active Active
- 2019-06-10 TW TW108119890A patent/TWI707683B/zh active
- 2019-06-11 PT PT231557471T patent/PT4219487T/pt unknown
- 2019-06-11 LT LTEPPCT/IB2019/054867T patent/LT3806955T/lt unknown
- 2019-06-11 JP JP2020569190A patent/JP6916968B1/ja active Active
- 2019-06-11 MA MA64510A patent/MA64510B1/fr unknown
- 2019-06-11 ES ES23155747T patent/ES3012643T3/es active Active
- 2019-06-11 HR HRP20230631TT patent/HRP20230631T1/hr unknown
- 2019-06-11 RS RS20230504A patent/RS64323B9/sr unknown
- 2019-06-11 AU AU2019285491A patent/AU2019285491B2/en active Active
- 2019-06-11 PE PE2023003553A patent/PE20240584A1/es unknown
- 2019-06-11 IL IL279300A patent/IL279300B2/en unknown
- 2019-06-11 EP EP19733151.5A patent/EP3806955B9/en active Active
- 2019-06-11 ES ES19733151T patent/ES2949954T3/es active Active
- 2019-06-11 CN CN201980053632.5A patent/CN112533674B/zh active Active
- 2019-06-11 CU CU2020000099A patent/CU20200099A7/es unknown
- 2019-06-11 DK DK19733151.5T patent/DK3806955T3/da active
- 2019-06-11 MD MDE20210363T patent/MD3806955T3/ro unknown
- 2019-06-11 FI FIEP19733151.5T patent/FI3806955T3/fi active
- 2019-06-11 CN CN202411489408.XA patent/CN119462622A/zh active Pending
- 2019-06-11 HU HUE19733151A patent/HUE063074T2/hu unknown
- 2019-06-11 WO PCT/IB2019/054867 patent/WO2019239319A1/en active IP Right Grant
- 2019-06-11 DK DK23155747.1T patent/DK4219487T5/da active
- 2019-06-11 BR BR112020024470-8A patent/BR112020024470A2/pt unknown
- 2019-06-11 MD MDE20240311T patent/MD4219487T3/ro unknown
- 2019-06-11 CN CN202411489409.4A patent/CN119431342A/zh active Pending
- 2019-06-11 SG SG11202011465QA patent/SG11202011465QA/en unknown
- 2019-06-11 FI FIEP23155747.1T patent/FI4219487T3/fi active
- 2019-06-11 UA UAA202007608A patent/UA124371C2/uk unknown
- 2019-06-11 PL PL19733151.5T patent/PL3806955T3/pl unknown
- 2019-06-11 SI SI201930570T patent/SI3806955T1/sl unknown
- 2019-06-11 CN CN202411488573.3A patent/CN119462621A/zh active Pending
- 2019-06-11 NZ NZ770240A patent/NZ770240A/en unknown
- 2019-06-11 GE GEAP201915517A patent/GEP20237453B/en unknown
- 2019-06-11 HR HRP20250099TT patent/HRP20250099T1/hr unknown
- 2019-06-11 LT LTEP23155747.1T patent/LT4219487T/lt unknown
- 2019-06-11 RS RS20250036A patent/RS66418B9/sr unknown
- 2019-06-11 HU HUE23155747A patent/HUE070423T2/hu unknown
- 2019-06-11 MX MX2020013625A patent/MX389121B/es unknown
- 2019-06-11 PT PT197331515T patent/PT3806955T/pt unknown
- 2019-06-11 KR KR1020217000940A patent/KR102542199B1/ko active Active
- 2019-06-11 PE PE2020001993A patent/PE20211601A1/es unknown
- 2019-06-11 PL PL23155747.1T patent/PL4219487T3/pl unknown
- 2019-06-11 EP EP23155747.1A patent/EP4219487B9/en active Active
- 2019-06-11 CR CR20200612A patent/CR20200612A/es unknown
- 2019-06-12 UY UY0001038261A patent/UY38261A/es not_active Application Discontinuation
- 2019-08-08 US US16/535,553 patent/US10683281B2/en active Active
- 2019-08-08 US US16/535,616 patent/US10676465B2/en active Active
-
2020
- 2020-12-01 NI NI202000091A patent/NI202000091A/es unknown
- 2020-12-02 PH PH12020552069A patent/PH12020552069A1/en unknown
- 2020-12-04 EC ECSENADI202078651A patent/ECSP20078651A/es unknown
- 2020-12-04 ZA ZA2020/07572A patent/ZA202007572B/en unknown
- 2020-12-07 CO CONC2020/0015305A patent/CO2020015305A2/es unknown
- 2020-12-11 CL CL2020003222A patent/CL2020003222A1/es unknown
-
2021
- 2021-02-09 US US17/171,385 patent/US20210163455A1/en not_active Abandoned
-
2023
- 2023-07-19 CY CY20231100347T patent/CY1126097T1/el unknown
- 2023-10-09 US US18/483,311 patent/US20240059679A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003222A1 (es) | Agonistas del receptor de glp-1 y usos de los mismos | |
| MX394736B (es) | Agonistas del receptor glp-1 y usos de los mismos. | |
| DOP2019000166A (es) | Agonistas receptores de glp-1 y usos de los mismos | |
| CL2018003569A1 (es) | Compuestos moduladores de fxr (nr1h4). | |
| CL2020000422A1 (es) | Composiciones de glp-1 y sus usos. | |
| CL2015002125A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| AR092475A1 (es) | Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r | |
| MX2020002262A (es) | Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer. | |
| AR105592A1 (es) | b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS | |
| CL2015002462A1 (es) | Polímero conjugado para entregar un agente bioactivo | |
| CO2020006443A2 (es) | Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
| NI201500063A (es) | Tratamiento de cáncer con pomalidomida en un individuo con daño renal | |
| CL2020003447A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas | |
| CL2020001846A1 (es) | Anticuerpos pac1 y sus usos | |
| CL2016002469A1 (es) | Sulfamidasa modificada y su producción | |
| CL2021002838A1 (es) | Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo. | |
| MX389809B (es) | Composiciones para el tratamiento o prevencion de sintomas vasomotores | |
| MX2022004945A (es) | Tratamiento de afecciones epilépticas con moduladores del receptor gabaa. | |
| EA202092674A1 (ru) | Агонисты рецептора glp-1 и их применение | |
| CR20150530A (es) | Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina | |
| UY35662A (es) | Derivados de espiroindolina y composiciones farmacéuticas de los mismos | |
| AR113814A1 (es) | Métodos y composiciones para dosificar linfocitos t con receptor del antígeno quimérico alógenos |